Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Giving oral Cabergoline or calcium infusion in women at high risk for developing ovarian hyperstimulation syndrome in context of assisted reproductive technologies aiming in its prevention
Women undergoing in vitro fertilization or intracytoplasmic sperm injection whom were at high risk for developing ovarian hyperstimuation syndrome were received either oral Cabergoline.5mg tablets for 7days starting on ovum pick up day and continued for 7days or received 10ml of 10%calcium gluconate in 200ml normal saline on ovum pick up day and continued for 4days
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Calcium infusion | Active Comparator | 10ml 10%calcium gluconate in 200ml normal saline solution given intravenously over thirty minutes, on ovum pick up day and continued for 4days |
|
| Oral Cabergoline | Active Comparator | Receiving oral Cabergoline (cabergamon 0.5 milligram tablet ) from ovum pick up day and continued for 7days,once daily |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oral Cabergoline | Drug | Giving oral Cabergoline tablet 0.5 milligram daily starting on ovum pick up day and continued for seven days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of ovarian hyperstimuation syndrome | Clinical condition occurred in context of assisted reproductive technologies in which there serous sacs fluid accumulation and hemoconcentration | 20 days from ovum pick up day |
| Measure | Description | Time Frame |
|---|---|---|
| Types of ovarian hyperstimuation syndrome and severity | Clinical severity either mild ,moderate or severe and its type either early or late onst | 20 days from ovum pick up day |
| Chemical pregnancy |
Not provided
Inclusion Criteria:
Exclusion Criteria:women with other endocrinopathy as congenital adrenal hyperplasia , hyperprolactinemia,diabetes
-
Women undergoing assisted reproductive technologies
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ashraf N Elmantwe, MD | Benha University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ashraf nassif Elmantwe | Cairo | Elqalopia | 5131 | Egypt |
Contact investigators
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000077465 | Cabergoline |
| D002125 | Calcium Gluconate |
| D002118 | Calcium |
| ID | Term |
|---|---|
| D004873 | Ergolines |
| D004876 | Ergot Alkaloids |
| D000470 | Alkaloids |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Calcium Gluconate | Drug | Giving 10 ml of 10 % calcium gluconate on 200 ml normal saline solution o.9% intravenously over thirty minutes starting on ovum pick up day and continued for four days |
|
|
Positive human chorionic Gonadotropin in blood
| 14 day from embryos transfer day |
| Clinical pregnancy | Intrauterine gestational sac | 5 week from embryos transfer day |
| D006576 |
| Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D005942 | Gluconates |
| D013400 | Sugar Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D006880 | Hydroxy Acids |
| D002241 | Carbohydrates |
| D008673 | Metals, Alkaline Earth |
| D004602 | Elements |
| D007287 | Inorganic Chemicals |
| D008670 | Metals |
| D001779 | Blood Coagulation Factors |
| D001685 | Biological Factors |